TLN2

Across TCGA pan-cancer cohorts, TLN2 Mutation is linked to patient survival in 13 of 34 cancer types, making it a survival-associated TLN2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TLN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TLN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

MESO, KIRC, and UCEC are the cancer types where TLN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	36	view →
KIRC	OS	Median	All	0.493	0.885	.003	20	view →
UCEC	OS	Median	II,III,IV	0.901	0.316	.012	18	view →
BRCA	OS	Median	III,IV	0.211	0.833	<.001	12	view →
COAD	OS	Median	III,IV	0.140	0.792	<.001	9	view →
READ	OS	Median	III,IV	0.644	0.932	<.001	8	view →
SKCM	DFS	Median	II,III,IV	0.853	0.667	.003	8	view →
LGG	OS	Median	All	0.306	0.799	.009	3	view →
HNSC	DFS	Median	All	0.836	0.307	.017	3	view →
ACC	DFS	Median	All	0.209	0.659	.027	3	view →
LIHC	OS	Median	All	1.000	0.497	.024	2	view →
DLBC	OS	Median	All	0.613	0.945	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

TLN2–MESO (OS)

Open the MESO breakdown →